Presentation Title

Depression Levels and SUD Treatment Goals

Start Date

November 2016

End Date

November 2016

Location

HUB 302-#30

Type of Presentation

Poster

Abstract

Major Depressive Disorder is highly comorbid with Substance Use Disorder (SUD), and the relationship between depression and substance use has substantial research behind it. Although it is documented that abstinence treatment plans can significantly reduce depressive symptoms in individuals undergoing SUD treatment (Brown & Schuckit, 1988), little research has been done to evaluate the relationship between depressive symptoms and moderation-based treatment plans among this population.

We attempted to evaluate the efficacy of SUD treatment on reducing depressive symptoms by comparing groups separated by their treatment goals of either moderation or abstinence. Depressive symptoms were measured using the BDI-II. Both groups were compared at intake and after three months of treatment to determine the effect of SUD treatment on depressive symptoms.

After three months of treatment, the BDI-II scores of the moderation group (n = 16) were significantly lower (p < .05) than those of the abstinence group (n = 16). These results suggest that treatment goal can have an effect on an individual’s depressive symptoms over the course of SUD treatment. Such findings allow us to assess the efficacy of moderation treatment on overall quality of life for clients.

This document is currently not available here.

Share

COinS
 
Nov 12th, 4:00 PM Nov 12th, 5:00 PM

Depression Levels and SUD Treatment Goals

HUB 302-#30

Major Depressive Disorder is highly comorbid with Substance Use Disorder (SUD), and the relationship between depression and substance use has substantial research behind it. Although it is documented that abstinence treatment plans can significantly reduce depressive symptoms in individuals undergoing SUD treatment (Brown & Schuckit, 1988), little research has been done to evaluate the relationship between depressive symptoms and moderation-based treatment plans among this population.

We attempted to evaluate the efficacy of SUD treatment on reducing depressive symptoms by comparing groups separated by their treatment goals of either moderation or abstinence. Depressive symptoms were measured using the BDI-II. Both groups were compared at intake and after three months of treatment to determine the effect of SUD treatment on depressive symptoms.

After three months of treatment, the BDI-II scores of the moderation group (n = 16) were significantly lower (p < .05) than those of the abstinence group (n = 16). These results suggest that treatment goal can have an effect on an individual’s depressive symptoms over the course of SUD treatment. Such findings allow us to assess the efficacy of moderation treatment on overall quality of life for clients.